Citations

Clear

13603 citation(s) found for "_, _".

Suicidal Ideation, Behaviors, and Deaths in People With Ménière's Disease: A Systematic Review
McCray, Lauren R. , Farmer, Hannah G., Nguyen, Shaun A. , Nguyen, Jacqueline P. , Kil, Jonathan, Staab, Jeffrey P. , Rizk, Habib G.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | March 11, 2025 | Volume: 172 | Issue: 6 | Pages: 1866-1873

10.1002/ohn.1216 | PMID 40062673 Get It

AbstractObjectiveTo assess relations between Ménière's disease and suicidality, measured by suicidal ideation, suicidal behaviors, and death by suicide.Data SourcesCINAHL, Cochrane Library, PubMed, PsycINFO, and SCOPUS databases were searched from inception through July 2, 2024.Review MethodsObservational studies related to suicidality in patients with Ménière's disease were included. Non‐English language papers, editorials, and studies on vestibular disorders not specified as Ménière's disease were excluded. The Risk Of Bias In Nonrandomized Studies‐of Exposure tool was used for cohort and qualitative studies, and the Joanna Briggs Institute critical appraisal checklist was used for case‐control studies.ResultsFour studies (n = 168,566) were included in our review. Two cohort studies found significantly increased adjusted hazard ratios of 2.1 (95% CI: 2.0‐2.2) for death by suicide and 7.6 (95% CI: 4.4‐13.3) for suicidal behaviors, respectively, in patients with Ménière's disease compared to the control population after their diagnosis. However, a case‐control study found no significant difference in the prevalence of suicidal ideation or behaviors prior to the date of diagnosis in patients with Ménière's disease compared to the control population (0.9% vs 0.8%; P = .44). In addition, one patient with Ménière's disease expressed suicidal ideation in the qualitative study.ConclusionPatients may experience variable responses to Ménière's disease. Thus, otolaryngologists should be mindful of the potential for suicidality in patients with Ménière's disease.
Posttransplant HBV Vaccine Compliance, Seroprotection, and Kinetics of Hepatitis B Surface Antibody in Thoracic Organ Transplant Recipients
Chiu, Chia‐Yu , Sampathkumar, Priya , Brumble, Lisa , Vikram, Holenarasipur R. , Watt, Kymberly D., Beam, Elena , Vikram, Holenarasipur R. , Beam, Elena , Chiu, Chia-Yu

Mayo Clinic

Transplant Infectious Disease | March 11, 2025 | Volume: 27 | Issue: 3 | Pages: No page available

10.1111/tid.70015 | PMID 39995014 Get It

ABSTRACTIntroductionVaccination is crucial to the thoracic solid organ transplant (SOT) population to reduce vaccine‐preventable infection. However, data on posttransplant hepatitis B virus (HBV) vaccination compliance and vaccine‐induced seroprotection are lacking.MethodsWe conducted a retrospective study of adult thoracic organ (heart and lung) transplant recipients at Mayo Clinic sites in Minnesota, Arizona, and Florida between January 2018 and August 2023. Recombivax HB was used before 2020, and Heplisav‐B was preferred after 2020. Recipients with posttransplant hepatitis B surface antibody (HBsAb) < 10 IU/L were eligible for the HBV vaccine. HBV seroprotection was defined as an HBsAb ≥ 10 IU/L.ResultsA total of 1116 recipients were evaluated, all of whom underwent posttransplant HBsAb testing. Of these, 751 (67%) had an HBsAb level < 10 IU/L and were eligible for posttransplant HBV vaccination. Of the eligible recipients, 117 (16%) completed the HBV vaccine series during the study period. Among these 117 recipients, 40 (34%) had their HBsAb levels rechecked after completing the vaccine series, with a seroprotection rate of 37.5% (15/40). There was no statistically significant difference in the seroprotection rates between Heplisav‐B and Recombivax HB vaccines (39% [13/33] vs. 29% [2/7]; p = 0.691). In addition, HBsAb levels were lowest at week 2 but rebounded at week 4 posttransplant and pretransplant HBsAb levels of ≥100 IU/L ensured 5‐year seroprotection.ConclusionSuboptimal compliance with HBV vaccination and poor vaccine‐induced seroprotection occur in thoracic organ transplant recipients, regardless of the vaccine used. These findings underscore the necessity of enhancing vaccination strategies for SOT recipients. image
Virtual reality for menopause symptom management: opportunities, challenges, and next steps
Safwan, Nancy , Suchak, Karisma , Liran, Omer , Kingsberg, Sheryl A. , Spiegel, Brennan , Spiegel, Brennan , Safwan, Nancy , Shufelt, Chrisandra , Faubion, Stephanie S.

Mayo Clinic

Menopause | March 11, 2025 | Volume: 32 | Issue: 5 | Pages: 475-480

10.1097/gme.0000000000002529 | PMID 40067758 Get It

Importance and Objective: Menopause is the natural cessation of ovarian function, typically occurring at a mean age of 52 years in the United States. Vasomotor symptoms (VMS; hot flashes and night sweats) affect over 75% of midlife women and typically last 7 to 9 years, with only 54% seeking medical attention. Although hormone therapy is the most effective treatment for VMS, <4% of women currently use it, primarily due to safety concerns. There is evidence that cognitive behavioral therapy (CBT) is an effective management strategy for VMS. Virtual reality (VR) has shown promise in delivering an immersive form of CBT for various medical conditions, including acute and chronic pain, sleep, and mood disorders, potentially overcoming barriers such as access and cost while improving quality of life. This narrative review aims to summarize the existing literature on VR for managing menopause symptoms. Methods: A comprehensive literature review was conducted through PubMed and Medline databases. The search focused on keyword combinations related to VR, artificial intelligence, and menopause symptoms. Discussion and Conclusion: The search yielded one study specifically targeting symptoms related to menopause. A pilot study (n = 42) evaluating an immersive VR and artificial intelligence intervention based on CBT and mindfulness techniques for managing hot flashes in women with breast or ovarian cancer demonstrated a significant reduction in frequency of hot flashes ( P < 0.01) and improvements in sleep quality, mood, anxiety, stress, and overall quality of life. However, these women experienced hot flashes that might have been associated with their cancer diagnosis or treatment rather than relating specifically to menopause, potentially limiting the generalizability of the findings to women with menopause symptoms. Although VR has shown effectiveness in delivering CBT for other conditions, there remains a significant gap in research on its specific use for menopause-related symptoms.
eLife assessment: Propionyl-CoA carboxylase subunit B regulates anti-tumor T cells in a pancreatic cancer mouse model
Rogers, Laura Q. , Rogers, Laura

Mayo Clinic

No container title available | March 11, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.96925.2.sa0 Get It

Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer
Chen, Li , Mansfield, Aaron S. , Lheureux, Stéphanie , O’Connor, C.J., Zamboni, Beth A., Patel, Kashish, McKee, Tawnya C., Moscow, Jeffrey A. , Zamboni, William C. , Mansfield, Aaron S , Lheureux, Stephanie , Moscow, Jeffrey A , Lucas, Andrew T.

Mayo Clinic

Clinical and Translational Science | March 11, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1111/cts.70178 | PMID 40051118 Get It

ABSTRACTAnetumab ravtansine, like other ADC drugs, has high inter‐patient variability in its pharmacokinetic (PK) and pharmacodynamic (PD) outcomes, which raises concerns about whether current dosing regimens are optimal for patients. The objective of this study was to evaluate covariates, especially body habitus and the innate immune system (IIS), which may affect anetumab ravtansine PK and PD as part of two clinical trials in patients with ovarian cancer and mesothelioma. Biomarkers of Fcγ receptors(FcγR) CD64 on IIS cells, total body weight (TBW), body surface area (BSA), and other covariates, such as sex and age, were analyzed for an association with anetumab ravtansine PK. Higher FcγR CD64, TBW, and BSA were associated with higher clearance (CL) of anetumab ravtansine (p < 0.05). However, there was no relationship between TBW or BSA and FcγR CD64. Female patients had a lower anetumab ravtansine CL (0.030 ± 0.007 L/h) compared to male patients (0.042 ± 0.006 L/h) (p < 0.05). In both studies, patients with stable disease (SD) and partial response (PR) had higher anetumab ravtansine AUC0‐inf compared to patients with progressive disease (PD). Individualizing the dose of anetumab ravtansine and potentially other ADCs based only on TBW is not optimal, whereas precision dosing of an ADC based on the inclusion of novel metrics of IIS biomarkers, body habitus, and sex may be more appropriate to reduce variability in PK exposure, reduce toxicity, and improve response.
Definitions, diagnosis, and management of postoperative recurrence in Crohn’s disease patients with permanent ileostomy—a systematic review and meta-analysis
Abushamma, Suha , Yadete, Tesfaye , Nero, Neil , Falloon, Katherine , Parker, Claire E. , Ahuja, Vineet, Armuzzi, Alessandro , Bemelman, Willem A. , Bruining, David H. , Feagan, Brian G. , Hart, Ailsa, Leong, Rupert W. , Narula, Neeraj , Raine, Tim , Singh, Siddharth , Sparrow, Miles , Spinelli, Antonino , Koughnett, Julie Ann Van, Solitano, Virginia , Yuan, Yuhong , Rieder, Florian , Deepak, Parakkal , Dignass, Axel , Fulmer, Clifton , Halfvarson, Jonas , Holubar, Stefan D , Ma, C , Magro, F , McCurdy, Jeffrey D , Narula, Neeraj , Panes, Julian , Raine, Tim , Regueiro, Miguel , Spinelli, Antonino , Rieder, Florian , Solitano, Virginia , Leong, Rupert W , Abreu, María T. , Ahuja, Vineet , Deepak, Parakkal , Dotan, Iris , Fulmer, Clifton G. , Hart, Ailsa , Holubar, Stefan D. , Ma, Christopher , Magro, Fernando , Panés, Julián , Regueiro, Miguel , Rogler, Gerhard , Vuyyuru, Sudheer K. , Jairath, Vipul

Mayo Clinic

Journal of Crohn's and Colitis | March 11, 2025 | Volume: 19 | Issue: 4 | Pages: No page available

10.1093/ecco-jcc/jjaf041 | PMID 40066499 Get It

Abstract Background and Aims Over 10% of patients with Crohn’s disease require permanent ileostomy. We aimed to summarize the existing data on diagnosis, definitions of recurrence, and management of Crohn’s disease patients with permanent ileostomy. Methods MEDLINE, Embase, and CENTRAL databases were searched from inception to February 6, 2024. Randomized controlled trials, cohort and cross-sectional studies, and case series of more than 5 patients reporting on postoperative recurrence or the need for surgery in patients with Crohn’s disease and permanent ileostomy were included. Search results were independently screened, and full text of all titles meeting eligibility criteria was obtained. Outcomes of interest included diagnostic techniques, recurrence definitions, and management approaches. We estimated pooled rates (with 95% confidence interval [CI]) of recurrence. Results Thirty cohort studies including 2055 Crohn’s patients with permanent ileostomy were included (53% female, median age at the time of ileostomy creation 32 years, the most common reason for ileostomy was refractory disease). The postoperative recurrence rate was 27% (95% CI, 21.3–33.3, 26 studies, 451/1805 patients). Modalities for diagnosis of Crohn’s disease recurrence were symptoms (15 studies), endoscopy (4 studies), histology from endoscopic biopsies (2 studies), imaging (5 studies), and surgery (22 studies). The reported definitions of recurrence for each modality were heterogeneous. Conclusions There is a lack of standardized monitoring tools and criteria for diagnosing recurrence in patients with Crohn’s disease and permanent ileostomy. The results of this systematic review will form the basis of a global expert recommendation exercise focused on developing management standards and trial endpoints for this condition.
TP53 ‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
Shah, Meera , Arber, Daniel A. , Hiwase, Devendra , Shah, Mithun V , Hiwase, Devendra , Arber, Daniel A

Mayo Clinic

American Journal of Hematology | March 11, 2025 | Volume: 100 | Issue: S4 | Pages: 88-115

10.1002/ajh.27655 | PMID 40066944 Get It

ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations ( TP53 mut ) and present immense challenges due to inherent chemoresistance and poor outcomes. As TP53 mut are more common in older individuals and those with secondary/therapy‐related myeloid neoplasms (MN), their incidence is expected to increase with an aging population and rising proportion of cancer survivors. Treatments used for other MN—intensive chemotherapy, hypomethylating agents, and the BCL‐2 inhibitor venetoclax—do not improve the survival of TP53 mut MN patients meaningfully. Additionally, further development of many promising agents has been discontinued, highlighting the challenges. Widespread acknowledgment of these problems led to the recognition of TP53 mut MN as a distinct entity in the 5th edition of the World Health Organization and International Consensus Classifications. However, critical discrepancies between the two classifications may lead to under‐ or overestimation of the prognostic risk. Here, we review recent advances in the biology, diagnosis, and treatment of TP53 mut MN. The development of TP53 mut MN is positioned at the intersection of age, hereditary predisposition, and anti‐cancer therapies. Precursor TP53 mut clones can be detected years prior to the eventual leukemic transformation—raising the possibility of early intervention. We discuss the two classification systems and the bearing of the discrepancies between the two on timely and effective management. We provide novel evidence in the areas of discrepancies. Finally, we review the current therapeutic landscape and the obvious limitations of the currently used therapies.
Choice of Anesthetic for Laparoscopic Bariatric Surgery Can Reduce the Use of Rescue Antiemetics in Postanesthesia Recovery Room: A Retrospective Observational Study
Šprung, Juraj , Ghanem, Omar M. , Lu, Lauren , Salame, Marita , Schroeder, Darrell R., Schroeder, Darrell R. , Lu, Lauren Y, Sprung, J , Schroeder, Darrell , Warner, David O. , Weingarten, Toby N.

Mayo Clinic

Surgical Laparoscopy, Endoscopy & Percutaneous Techniques | March 10, 2025 | Volume: 35 | Issue: 2 | Pages: No page available

10.1097/sle.0000000000001341 | PMID 40063267 Get It

Objective: Postoperative nausea and vomiting (PONV) is a frequent adverse event after bariatric surgery and is associated with patient dissatisfaction and increased health care burden. Aggressive multimodal antiemetic prophylaxis and the use of propofol infusion during anesthesia are associated with the reduction of PONV. In this study, we examined the use of rescue antiemetics following bariatric surgery performed with 3 different anesthetic strategies designed to reduce PONV: (1) primary volatile (VOL) anesthetic and propofol (PROP) infusion (VOL+PROP), (2) volatile anesthetic with propofol and dexmedetomidine (DEX) infusions (VOL+PROP+DEX), or (3) opioid-sparing total intravenous anesthesia (PROP+DEX). Methods: In this retrospective observational study, we included patients undergoing bariatric surgery from 2018-2022 who received 1 of 3 anesthetics: (1) VOL+PROP, (2) VOL+PROP+DEX, or (3) opioid-sparing PROP+DEX without a VOL. Inverse probability of treatment weighting analysis determined the association between the need for rescue-antiemetics in the postanesthesia care unit (PACU) and following PACU discharge. Results: Three hundred thirty-two patients received VOL+PROP, 354 VOL+PROP+DEX, and 166 PROP+DEX, and all received prophylactic antiemetics during surgery. After surgery, the PROP+DEX patients received fewer rescue antiemetics in the PACU compared with VOL+PROP (11% vs. 24%, P=0.002), and VOL+PROP+DEX fewer compared with VOL+PROP (16% vs. 24%, P=0.023). This differential antinausea effect was limited to PACU stay only. Rescue antiemetic use increased across all anesthetic management groups following PACU discharge until midnight on the day of surgery (ranging from 38% to 46% across groups, P=0.71) and through the first postoperative day (ranging from 47% to 57% across groups, P=0.20). Conclusions: The benefit associated with anesthetic strategies designed to reduce PONV was present but did not persist past PACU discharge. This finding suggests that aggressive perioperative multimodal antiemetic prophylaxis combined with anesthetic strategies designed to prevent PONV after bariatric surgery have only a short-lived effect, thus health care staff in hospital wards may expect to encounter high rates of PONV in these patients. There is a need for the development of novel antinausea treatments to reduce the rate of this frequent postoperative complication.
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives
Loscocco, Giuseppe Gaetano , Loscocco, Giuseppe Gaetano , Guglielmelli, Paola

Mayo Clinic

American Journal of Hematology | March 10, 2025 | Volume: 100 | Issue: S4 | Pages: 30-50

10.1002/ajh.27658 | PMID 40062529 Get It

ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2 , CALR , or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as well as splenomegaly, constitutional symptoms, ineffective erythropoiesis, extramedullary hematopoiesis, and a risk of leukemic progression and shortened survival. Therapy can range from observation alone in lower‐risk and asymptomatic patients to allogeneic hematopoietic stem cell transplantation, which is the only potentially curative treatment capable of prolonging survival, although burdened by significant morbidity and mortality. The discovery of the JAK2 V617F mutation prompted the development of JAK inhibitors (JAKi) including the first‐in‐class JAK1/JAK2 inhibitor ruxolitinib and subsequent approval of fedratinib, pacritinib, and momelotinib. The latter has shown erythropoietic benefits by suppressing hepcidin expression via activin A receptor type 1 (ACVR1) inhibition, as well as reducing splenomegaly and symptoms. However, the current JAKi behave as anti‐inflammatory drugs without a major impact on survival or disease progression. A better understanding of the genetics, mechanisms of fibrosis, cytopenia, and the role of inflammatory cytokines has led to the development of numerous therapeutic agents that target epigenetic regulation, signaling, telomerase, cell cycle, and apoptosis, nuclear export, and pro‐fibrotic cytokines. Selective JAK2 V617F inhibitors and targeting of mutant CALR by immunotherapy are the most intriguing and promising approaches. This review focuses on approved and experimental treatments for MF, highlighting their biological background.
Comment on “Getting back on the curve: Reimagining individualized, sustainable residency training for the critical care pharmacist”
Emery, Darrick, Nei, Scott D. , Nei, Scott, Emery, Darrick

Mayo Clinic

American Journal of Health-System Pharmacy | March 10, 2025 | Volume: 82 | Issue: 16 | Pages: 864-865

10.1093/ajhp/zxaf065 | PMID 40062540 Get It